The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers
- Category: Press Room
- Published on Thursday, 01 March 2007 02:00
- Hits: 6715
Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field.
BARCELONA, Spain | Mar 01, 2007 | Merck & Co posted Q4/2006 sales of US$ 42 mln with its first-in-class dipeptidyl peptidase IV(DPP-IV) inhibitor Januvia. FDA’s recent request for more clinical data to meet conditions set forth in the approvable letter of Novartis’ NDA of the DPP-IV inhibitor Galvus will aid Merck to maintain and extend its competitive edge in the field. At least 13 further DPP-IV inhibitors are in clinical development with eight in advanced phase II or III stages. However, the first Big Pharma companies have abandoned the field, partly due to undisclosed safety issues, unsatisfactory clinical results or better alternatives. Available data show differences in duration of action and anticipated dosing frequency. These results were found in a search conducted by La Merie Business Intelligence and can be acquired at the Online Store PipelineReview.com.
The high interest of the pharmaceutical industry in DPP-IV inhibitors reflects the market attractivity. The WHO estimates that globally over 170 mln people have diabetes, with type 2 diabetes accounting for 90 % to 95 %. By 2030, the prevalence of diabetes is predicted to double, driven by adverse lifestyle changes. Dipeptidyl peptidase IV is an enzyme that rapidly inactivates the insulinotropic hormone glucagon-like peptide-1 (GLP-1). Inhibition of dipeptidyl peptidase IV by DPP-IV inhibitors enhances the hormone activity of GLP-1 and other bioactive peptides (GIP, PACAP38 and GRP), thereby stimulating the release of insulin and reducing the secretion of glucagon. Both effects contribute to regulation of the elevated blood glucose levels in type 2 diabetic patients as measured by hemoglobin A1c (HbA1c).
Available clinical data suggest that long term treatment with DPP-IV inhibitors was well tolerated with very low rates of hypoglycaemia and was not associated with weight gain or gastrointestinal disturbances. The DPP-IV inhibitors are being evaluated as both monotherapy and in combination with other standard antidiabetic drugs, e.g. metformin. The major advantages of DPP-IV inhibitors are the ability to achieve sustainable reductions in HbA1c with an orally administered, well tolerated agent. Other classes of new antidiabetic medications include GLP-1 agonists and dual PPAR agonists. However, GLP-1 agonists require administration by injection and dual PPAR agonists are associated with safety concerns.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. A free R&D Newletter conveniently brings via e-mail a daily selection of the most interesting news from biopharmaceutical R&D. For more information visit PipelineReview.com.
SOURCE: La Merie Business Intelligence